Contributor Page
Carpmaels & Ransford LLP
Email  |  Articles
Contact Details
Tel: +44 7 242 8692
Fax: +44 7 405 4166
One Southampton Row
By Michael Nielsen, Gary Small
A recent decision from the UK Court of Appeal in Adaptive Spectrum and Signal Alignment Inc. v British Telecommunications Plc. has shown that the UK courts are prepared to impose injunctions on big telecoms operators, but that in doing so consideration may well be given to the effect an injunction will have on the public.
By Jennifer Archibald, John Brunner
The UK Court of Appeal recently issued a judgment in Lantana Ltd’s application which provides a useful summary of tests for excluded subject matter in the UK set out in previous cases.
By Richard Newell, John Brunner
The UK Intellectual Property Office (UKIPO)’s opinions service has been given more substance, and the Office has been given the power to revoke patents in certain situations.
By Ben Husband, John Brunner
Advocate General issues his opinion in Huawei v ZTE in its referral to the Court of Justice
By Stuart Forrest, Ian Kirby
The caps that are in place for the Intellectual Property Enterprise Court (IPEC), formerly known as the Patents County Court (PCC), provide claimants and defendants alike with certainty with regard to damages/account of profits and orders in relation to costs.
By Henrietta Rooney, Ian Kirby
There was good news today for the Unitary Patent system. The AG’s opinion stated that Spain’s latest challenges to the UPC are unfounded, that the legal basis for the disputed regulations are valid, affirmed the role of the EPO in the new Unitary Patent system and backed the use of a limited number of languages for the new Unitary Patents.
By Carpmaels & Ransford
UK courts have the power to dispose of all or part of a case without a trial if there is no real prospect of success.
By Carpmaels & Ransford
European patent law offers extra protection for pharmaceuticals that is not available for medical devices.
By Henrietta Rooney, Glyn Truscott
In the latest development to the patentability of human stem cells, the Advocate General (AG) has recommended that stem cells derived from parthenogenically activated oocytes should not be excluded from patentability any longer.
By Chloe Grover, Mark Abthorpe
The IP Bill recently received Royal Assent and became the IP Act 2014 ("the Act"). This article summarises the most significant changes to UK law relating to both patents and designs brought about by provisions in the Act that will start to come into force from 1st October 2014.
By Caroline Allen, John Brunner
The latest developments in 3D printing and the implications for IP protection.
By Anna Leathly, Glyn Truscott
Mr Justice Arnold in the Patents Court of the High Court of England and Wales (the ‘Patents Court’) initially refused a request by the patentee, Pharmacia, for a stay of UK revocation proceedings brought by Actavis, pending the outcome of opposition proceedings at the EPO based on three undertakings.
By Tanja Preissner, Daniel Wise
In a pro-patentee judgment, the UK High Court suggests that SPCs can be based on most types of claim provided that the product which is the subject of the SPC falls within the scope of the claim.
By Russell Woolley, Gillian Philips
As of 1st November 2014, the EPO is changing the way it searches PCT applications entering the European regional phase which are considered to relate to more than one invention.
By Susan Kirsch
In a decision dated 23rd May 2014, Mr Justice Arnold in the UK High Court dismissed Professor Shanks' appeal and upheld the UKIPO decision not to award Professor Shanks any employee inventor compensation.